Prostate Cancer – Starting at the Beginning
BY MARK SCHOLZ, MD After sitting down with a new patient Tom, a charming 80-year-old man who was recently found to have a prostate nodule and a PSA elevated up to 50, …
Oligometastatic Prostate Cancer Part II
BY MARK SCHOLZ, MD In Part One, I reviewed some of the background theories on how treating metastatic disease, when only a limited number of metastatic sites exist, might be beneficial, …
Oligometastatic Prostate Cancer Part I
BY MARK SCHOLZ, MD Over the last 15 years or so, modern thinking about how to treat the early stages of prostate metastases has been changing. Various studies are showing …
When PSA Doubling Time Shows a Prostate Cancer Relapse in Men
BY MARK SCHOLZ, MD One cannot really talk intelligently about prostate cancer without a working knowledge of the PSA blood test. Most people are familiar with using PSA to diagnose prostate …
Evaluate PSA with Imaging, Not Random Biopsy: Avoiding Unnecessary Radical Treatment
BY MARK SCHOLZ, MD Prostate cancer is the most common form of cancer in men. While some types of prostate cancer are life-threatening, some types are not. Recent media reports …
SIR-Spheres to Treat Liver Metastases from Prostate Cancer
BY MARK SCHOLZ, MD Metastases are what makes cancer dangerous. Uncontrolled cell growth disrupts normal organ function. Some organs, like lymph nodes for example, continue to function well, even when the cancer …
Zytiga —The Next Step after Lupron?
BY MARK SCHOLZ, MD It seems we have a national passion for prostate biopsies. A million men are biopsied every year. Two hundred thousand of them will be diagnosed with prostate cancer …
Starting Treatment Early for Metastatic Prostate Cancer: Part IV
BY MARK SCHOLZ, MD Recently, many new anticancer agents have become available for the treatment of prostate cancer—Zytiga, Xtandi, Xofigo, Provenge and Jevtana, but differing opinions about optimal combinations and sequencing …
Starting Treatment Early for Metastatic Prostate Cancer: Part III
BY MARK SCHOLZ, MD In Part I and II of this series of articles, the effectiveness treatment initiated at an earlier stage, with either Lupron or Provenge, was compared with the effectiveness of either …
Starting Treatment Early for Metastatic Prostate Cancer: Part II
BY MARK SCHOLZ, MD In 2010 the FDA approved Provenge for hormone-refractory prostate cancer. Provenge is a treatment that functions by enhancing the immune system. Some critics have called the effectiveness of …